



Minimum Latency & Types or Categories of Cancer

John Howard, M.D., Administrator
World Trade Center Health Program

Revision: May 1, 2013

(Replaces Administrator's *White Paper on Minimum Latency & Types of Cancer* dated October 17, 2012)

Note for May 1, 2013 Revision: As new scientific information becomes available to the World Trade Center (WTC) Program Administrator on minimum latencies for the types or categories of cancers on the List of WTC-Related Health Conditions found at 42 C.F.R. § 88.1, minimum latencies may be modified. The Administrator's May 1, 2013 revision to the *White Paper on Minimum Latency & Types or Categories of Cancer* changes minimum latencies for mesothelioma and the category of lymphoproliferative and hematopoietic cancers.

Executive Summary

The WTC Program Administrator has determined minimum latencies for the following five types or categories of cancer eligible for coverage in the WTC Health Program:

- (1) **Mesothelioma—11 years**, based on direct observation after exposure to mixed forms of asbestos, which represents a change from the October 17, 2012 version of the Administrator's *White Paper on Minimum Latency & Types or Categories of Cancer*;
- (2) **All solid cancers (other than mesothelioma, lymphoproliferative, thyroid, and childhood cancers)—4 years**, based on low estimates used for lifetime risk modeling of low-level ionizing radiation studies;
- (3) **Lymphoproliferative and hematopoietic cancers (including all types of leukemia and lymphoma)—0.4 years** (equivalent to 146 days), based on low estimates used for lifetime risk modeling of low-level ionizing radiation studies, which represents a change for lymphoproliferative cancers only from the October 17, 2012 version of the Administrator's *White Paper on Minimum Latency & Types of Categories of Cancer*;
- (4) **Thyroid cancer—2.5 years**, based on low estimates used for lifetime risk modeling of low-level ionizing radiation studies; and
- (5) **Childhood cancers (other than lymphoproliferative and hematopoietic cancers)—1 year**, based on the National Academy of Sciences findings.

I. Introduction

According to the James Zadroga 9/11 Health and Compensation Act of 2010 ("Act") (42 U.S.C. §§ 300mm to 300mm-61), a determination that an individual's 9/11 exposure is substantially likely to be a significant factor in aggravating, contributing to, or causing an individual's health condition must be made based on an assessment of the following: (1) the individual's exposure to airborne toxins, any other hazard, or any other adverse condition resulting from the terrorist attacks; and (2) the type of symptoms and temporal sequence of symptoms (42 U.S.C. § 300mm-22(a)(2)). With regard to the temporal sequence of symptoms, cancers do not occur immediately after exposure to a causative agent and they usually take many years up to several decades to manifest clinically. The formation of a tumor is a complex process, and tumor progression occurs by a sequence of randomly occurring changes in genetic material that alter cell functions such as proliferation, survival, and growth inhibition, as well as other cellular changes needed to overcome the normal barriers to becoming malignant. Based on the requirement in the Act to consider the temporal sequence of symptoms, the Administrator determined that a minimum time period (i.e., latency) must have elapsed between the initial date of the individual's 9/11 exposure and the date of the initial diagnosis of the individual's cancer for the cancer to be certified.

The assessment of minimum latency periods for various types or categories of cancer is straightforward when exposures occur at a single point in time or regularly. However, most human exposures to carcinogens vary significantly over time, making a precise determination of minimum latency periods difficult.

The basis for selecting minimum latencies to specific types or categories of cancer is described in the sections below. However, at the outset it is important to understand that the scientific literature assessing minimum latency periods for specific types of cancer is scarce. Estimates of minimum latencies are available in the scientific literature for only a small number of the covered cancers associated with exposure to carcinogenic agents present in the aftermath of the 9/11 attacks (also referred to as "9/11 agents"). Similarly, observations of minimum latencies are available for only a few of the cancers that the Administrator added to the List of WTC—Related Health Conditions ("List") eligible for coverage under the WTC Health Program associated with other agents.

Therefore, the Administrator derived minimum latency estimates using several methods based on the best available scientific evidence for each type or category of cancer considered.

II. Methods Used to Determine Minimum Latency Estimates (*Latency Methods*)

The four specific methods used by the Administrator to select minimum latency estimates for types or categories of cancer are described below in order of the best available science, as judged by the Administrator. The methods are as follows:

Latency Method 1: Studies reporting minimum latency estimates for cancer from a 9/11 agent based on direct observation of latencies.

In this approach, the population studied must be large enough to develop a reasonable estimate of the lower bound of the distribution of latencies, which is the estimate of the minimum latency.

Latency Method 2: Authoritative Recommendations

When estimates of minimum latency are not available using *Latency Method 1*, the Administrator reviewed available recommendations on minimum latency from authoritative bodies, such as the National Academy of Sciences, and selected the shortest latency period.

Latency Method 3: Studies reporting observed latencies for a cancer from another agent, with preference given to agents chemically analogous to a 9/11 agent.

In this approach, the population studied must be large enough to develop a reasonable estimate of the lower bound of the distribution of latencies, which is the estimate of the minimum latency.

Latency Method 4: Statistical Modeling

When estimates of minimum latency are not available from studies with direct observations of minimum latencies [*Latency Methods 1 and 3*], or from authoritative recommendations [*Latency Method 2*], the Administrator looks to estimates of the minimum latency periods used in statistical models and published in the scientific literature. The two modeling approaches are described below.

4A: Estimates of cancer latency obtained by statistical modeling in epidemiologic studies of the association between exposure to an agent and a type of cancer.

Using this method, an investigator excludes exposure for some period of time (e.g., 10 or 20 years) before diagnosis is made. Exposure time is excluded because any exposure that occurs *after* a cancer develops in an individual does not contribute to the developmental time for that cancer. Several time periods may be tested, and the time period that yields the strongest association between exposure and the cancer is used as the estimate of the minimum latency period.^{1 *}

4B: Estimates of cancer latency obtained from statistical models used to estimate the lifetime risk of low-level ionizing radiation-related cancers.

The use of a radiation-induced cancer latency estimate is supported by scientific literature indicating shared mechanisms of carcinogenesis that apply to most solid tumors.² Furthermore, cancers that may develop as a result of radiation exposure are indistinguishable from those that occur as a result of exposure to other carcinogens.³

If multiple estimates of minimum latency based on statistical modeling in epidemiologic studies were available in the scientific literature, the Administrator's policy is to resolve any uncertainties inherent in this method [*Latency Method 4*] in favor of the WTC Health Program member by selecting the shortest latency period.

* This procedure is referred to as "lagging" in epidemiologic studies.

The strength of the available scientific evidence for estimates of minimum latency for each type of cancer or category of cancer was evaluated. The Administrator selected minimum latencies for use in the evaluation of a case of cancer for certification in the WTC Health Program based on that evaluation.

III. Basis for Selecting Minimum Latencies

A. Mesothelioma

The basis for adding mesothelioma to the List was exposure to chrysotile asbestos, which was the only form of asbestos identified in any of the settled surface dust samples in the New York City disaster area.⁴ However, a literature search did not identify any studies which reported a minimum latency that was specific for chrysotile exposure [*Latency Method 1*] for more than a few individuals. All reported latencies in these studies were greater than 20 years. Also, the Administrator was unable to find recommendations on minimum latency from other authoritative sources [*Latency Method 2*]. Therefore, the Administrator has decided to rely on estimates of latency in the scientific literature for exposures to mixed forms of asbestos [*Latency Method 3*].

A review of 21 studies by Lanphear and Buncher covered a large variety of occupations, and identified 1,105 cases of asbestos-related mesothelioma.⁵ The studies reported a median latency period of 32 years, with 96% of cases diagnosed at least 20 years following initial exposure and 33% of cases diagnosed 40 years after initial exposure. Lanphear and Buncher reported a minimum latency of 11 years. The minimum latencies of malignant mesothelioma reported in other studies of exposures to mixed forms of asbestos ranged from 13 to 15 years.⁶⁻¹⁰

Therefore, based on the best available scientific evidence and following the methodology presented in this revised *White Paper on Minimum Latency and Types or Categories of Cancer*, the Administrator selected a minimum latency of 11 years for use in the evaluation of a case of mesothelioma for certification in the WTC Health Program. For a cancer occurring in a person less than 20 years of age, see Section III, E.

B. Solid Cancers (other than mesothelioma, lymphoproliferative, thyroid, and childhood cancers)

Latency estimates based on a small number of individuals in direct observational studies have been reported for a few of the solid cancers included on the List. Those latency estimates are as follows:

- The minimum interval between the onset of gastro-esophageal reflux disease (GERD) and diagnosis of esophageal cancer (latency) has been reported to be 20 years.¹¹ However, in individuals with GERD who have also been exposed to 9/11 agents acting as cancer initiators or promoters, the Administrator notes that the minimum latency may be significantly shortened;
- The minimum latency of 12 years has been reported for liver cancer associated with vinyl chloride exposure.¹² Additional 9/11 agents are known to cause liver cancer, however direct observations of latency [*Latency Methods 1 and 3*] or authoritative recommendations [*Latency Method 2*] are not available for those agents.

- Minimum latency estimates have been reported in the literature for lung cancer associated with exposure to asbestos (19 years),^{7, 13, 14} to chromium (5 years),¹⁴ and to soot (9 years).¹⁵ Additional 9/11 agents are known to cause lung cancer, however direct observations of latency [*Latency Methods 1 and 3*] or authoritative recommendations [*Latency Method 2*] are not available.

Latency estimates are available in the scientific literature for other covered solid cancers associated with exposures to agents not known to be present at the sites of the 9/11 terrorist attacks. For example, a minimum latency of 20 years has been reported for chlorinated biphenyl-related melanoma¹⁶ and a minimum latency of 4 years has been reported for urinary bladder cancer associated with aromatic amine exposure.¹⁷ Specific 9/11 agents are known to cause melanoma and bladder cancer, however direct observations of latency [*Latency Methods 1 and 3*] or authoritative recommendations [*Latency Method 2*] are not available.

For some types of solid cancers on the List, estimates of minimum latency were found in the scientific literature based on statistical modeling in epidemiologic studies of associations between an exposure and cancer [*Latency Method 4A*]. Estimates of latency using this method have been reported for nasopharyngeal cancer associated with formaldehyde exposure (15 years)¹⁸ and for asbestos-related cancer of the pleura (30 years).¹³

For solid cancers as a group, an estimate of minimum latency of 4 years is available from statistical modeling of risk between exposure to low-level ionizing radiation and solid cancers [*Latency Method 4B*].^{19, 20}

Therefore, based on the best available scientific evidence and following the methodology presented in this revised *White Paper on Minimum Latency and Types or Categories of Cancer*, the Administrator selected a minimum latency of 4 years for use in the evaluation of all types and categories of solid cancers other than mesothelioma, lymphoproliferative, thyroid, and childhood cancers) for certification in the WTC Health Program. For a cancer occurring in a person less than 20 years of age, see Section III, E.

C. Lymphoproliferative and Hematopoietic Cancers

Latency estimates vary widely for different lymphoproliferative and hematopoietic malignancies. For leukemia and lymphoma, direct observations of latency are not available in the literature for 9/11 agents [*Latency Method 1*]. Also, the Administrator was unable to find recommendations on minimum latency from other authoritative sources [*Latency Method 2*]. The only estimates of minimum latency found in the scientific literature were based on statistical modeling in epidemiologic studies of associations between an exposure and cancer [*Latency Methods 4A and 4B*]. The reported minimum latency estimate using statistical modeling in epidemiologic studies for acute non-lymphocytic leukemia and benzene exposure is 1.5 years,^{21, 22} and for lymphoproliferative and hematopoietic malignancies resulting from formaldehyde exposure is 2 years [*Latency Method 4A*].²³ For chronic lymphocytic leukemia, a minimum latency estimate of 15 years has been reported for ionizing radiation exposure [*Latency Method 4B*].²⁴ A minimum latency period of 2 years has been reported for non-Hodgkin lymphoma²⁵ following treatment of Hodgkin disease with chemotherapy and radiotherapy, which is similar to the latency for secondary acute leukemia [*Latency Method 3*].²⁶

Evaluation of the latencies of leukemias, including chronic lymphocytic leukemia, and lymphomas from exposures to occupational and environmental agents is difficult for a number of reasons. First, the nomenclature used in the histological classification of these diseases is in flux. Second, a particular lymphoid neoplasm may manifest both lymphoid and leukemic features. Third, there is substantial overlap in the estimates of latency periods for lymphomas, which range from 2 to 10 years, and leukemias, which range from 1.5 to 15 years. This similarity in estimates of the minimum latencies for lymphoproliferative and hematopoietic malignancies is demonstrated as noted above and in risk models for radiation-induced leukemia and for chemotherapy-related acute myelocytic leukemia,¹⁹ as well as acute non-lymphocytic leukemia from benzene exposure.²¹ Moreover, leukemia that develops after exposure to benzene is similar to atomic bomb irradiation or therapy-induced leukemia.²⁷

Although latencies based on direct observations for some types of lymphomas and leukemias have been reported in the scientific literature, the nomenclature, classification, and latency overlap issues discussed above cast doubt on the reliability of these observations for use in the WTC Health Program. For these reasons, the Administrator has decided to rely on the estimate of minimum latency for all lymphoproliferative and hematopoietic malignancies of 0.4 years based on low estimates used for lifetime risk modeling of low-level ionizing radiation studies for lymphomas and leukemias.²⁰

Therefore, based on the best available scientific evidence and following the methods presented in this revised *White Paper on Minimum Latency and Types or Categories of Cancer*, the Administrator has selected a minimum latency of 0.4 years or 146 days for use in the evaluation of cases of lymphoproliferative and hematopoietic cancers for certification in the WTC Health Program. For a lymphoproliferative or hematopoietic cancer occurring in a person less than 20 years of age, the Administrator has also selected this minimum latency of 0.4 years, see Section III,E.

D. Thyroid Cancer

For thyroid cancer, direct observations or estimates of latency for 9/11 agents (*Latency Method 1*) or other agents (*Latency Method 3*) are not available in the literature. Also, the Administrator was unable to find recommendations on minimum latency from other authoritative sources [*Latency Method 2*]. Therefore, the Administrator has decided to rely on estimates of minimum latency based on the statistical modeling of risk for associations between exposure to low-level ionizing radiation and thyroid cancer of 2.5 years [*Latency Method 4B*].²⁰

Therefore, based on the best available scientific evidence and following the methodology presented in this revised *White Paper on Minimum Latency and Types or Categories of Cancer*, the Administrator selected a minimum latency of 2.5 years for use in the evaluation of a case of thyroid cancer for certification in the WTC Health Program. For a cancer occurring in a person less than 20 years of age, see Section III,E.

E. Childhood Cancers

The most common cancers in children are leukemia (34%), brain and nervous system tumors (34%), lymphomas (8%), Wilms tumor of the kidney (5%), bone cancers (4%), rhabdomyosarcoma (3%), and retinoblastoma (3%).²⁸ One of the differences between childhood cancers and adult cancers is that

childhood cancers typically have a shorter latency period. After reviewing the scientific literature, the Administrator has determined that estimates of minimum latency by *Latency Methods 1, 3, and 4* are not available for this broad category of cancer types. However, the National Academy of Sciences has reported that childhood cancers have a latency period of 1 to 10 years [*Latency Method 2*].²⁹

Therefore, based on the best available scientific evidence and following the methodology presented in this revised *White Paper on Minimum Latency and Types or Categories of Cancer*, the Administrator selected a minimum latency of 1 year for use in the evaluation of cases of childhood cancer for certification in the WTC Health Program (excluding lymphoproliferative and hematopoietic cancers in children, for which the Administrator selected the minimum latency of 0.4 years). For purposes of the WTC Health Program, a childhood cancer means all types of cancer occurring in a person less than 20 years of age (42 C.F.R. §88.1).

IV. Summary

The Administrator has selected minimum latencies for the following five types or categories of cancer:

- (1) **Mesothelioma**—11 years;
- (2) **All solid cancers (other than mesothelioma, lymphoproliferative, thyroid, and childhood cancers)** — 4 years;
- (3) **Lymphoproliferative and hematopoietic cancers (including all types of leukemia and lymphoma)** — 0.4 years (146 days);
- (4) **Thyroid cancer** — 2.5 years; and
- (5) **Childhood cancers (other than lymphoproliferative and hematopoietic cancers)**—1 year.

List of References

1. Rothman KJ, Greenland S. *Modern Epidemiology*. 2nd ed. Philadelphia: Lippincott-Raven; 1998.
2. Baba AI, Cătoi C. *Comparative Oncology*. Bucharest: The Publishing House of the Romanian Academy; 2007.
3. United States Nuclear Regulatory Commission. Fact Sheet on Biological Effects of Radiation. Available at: <http://www.nrc.gov/reading-rm/doc-collections/fact-sheets/bio-effects-radiation.html>; 2011.
4. New York City Department of Health and Mental Hygiene, Agency for Toxic Substances and Disease Registry. Final technical report of the public health investigation to assess potential exposures to airborne and settled surface dust in residential areas of lower Manhattan; 2002.
5. Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. *J Occup Med*. 1992;34:718-721.
6. Kamp DW. Asbestos-induced lung diseases: an update. *Translational research : the journal of laboratory and clinical medicine*. 2009;153:143-152.
7. Selikoff IJ, Hammond EC, Seidman H. Latency of asbestos disease among insulation workers in the United States and Canada. *ACancer*. 1980;46:2736-2740.
8. Linton A, Vardy J, Clarke S, van Zandwijk N. The ticking time-bomb of asbestos: its insidious role in the development of malignant mesothelioma. *ACritical reviews in oncology/hematology*. 2012;84:200-212.
9. Bianchi C, Bianchi T. Malignant pleural mesothelioma in Italy. *Indian journal of occupational and environmental medicine*. 2009;13:80-83.
10. Bianchi C, Giarelli L, Grandi G, Brollo A, Ramani L, Zuch C. Latency periods in asbestos-related mesothelioma of the pleura. *AEur J Cancer Prev*. 1997;6:162-166.
11. den Hoed CM, van Blankenstein M, Dees J, Kuipers EJ. The minimal incubation period from the onset of Barrett's oesophagus to symptomatic adenocarcinoma. *ABr J Cancer*. 2011;105:200-205.
12. Leibel WK. A 25-year follow-up study of heavily exposed vinyl chloride workers in Germany. *Am J Ind Med*. 1996;29:446-458.
13. Magnani C, Ferrante D, Barone-Adesi F, et al. Cancer risk after cessation of asbestos exposure: a cohort study of Italian asbestos cement workers. *Occup Environ Med*. 2008;65:164-170.
14. Harding AH, Darnton A, Wegerdt J, McElvenny D. Mortality among British asbestos workers undergoing regular medical examinations (1971-2005). *Occup Environ Med*. 2009;66:487-495.
15. Barth PS, Hunt H. *A Worker's compensation and work-related illnesses and diseases*. Cambridge: MIT Press; 1980.
16. Loomis D, Browning SR, Schenck AP, Gregory E, Savitz D. ACancer mortality among electric utility workers exposed to polychlorinated biphenyls. *Occup Environ Med*. 1997;54:720-728.
17. Schulte PA, Ringen K, Hemstreet GP, Ward E. Occupational cancer of the urinary tract. *Occup Med*. 1987;2:85-107.

18. Hauptmann M, Lubin JH, Stewart PA, Hayes RB, Blair . AMortality from solid cancers among workers in formaldehyde industries. *Am J Epidemiol*. 2004;159:1117-1130.
19. National Research Council. Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2. Washington, DC: The National Academies Press; 2006.
20. Berrington de Gonzalez A, Apostoaei AJ, Veiga LHS, et al. RadRAT: a radiation risk assessment tool for lifetime cancer risk projection *J Radiol Prot*. 2012;32:205-222.
21. Hayes RB, Yin SN, Dosemeci M, et al. Benzene and the dose-related incidence of hematologic neoplasms in Chin. AChinese Academy of Preventive Medicine--National Cancer Institute Benzene Study Group. *J Natl Cancer Inst*. 1997;89:1065-1071.
22. Straube S, Westphal GA, Hallier E. Comment on: Implications of latency period between benzene exposure and development of leukemia—A synopsis of literature. *Chemico-Biological Interactions*. 2010;186:248-249.
23. Beane Freeman LE, Blair A, Lubin JH, et al. Mortality from lymphohematopoietic malignancies among workers in formaldehyde industries: the National Cancer Institute Cohort. *J Natl Cancer Inst*. 2009;101:751-761.
24. Richardson DB, Wing S, Schroeder J, Schmitz-Feuerhake I, Hoffmann W. Ionizing radiation and chronic lymphocytic leukemia. *AEviron Health Perspect*. 2005;113:1-5.
25. Bennett MH, MacLennan KA, Vaughan Hudson G, Vaughan Hudson B. Non-Hodgkin's lymphoma arising in patients treated for Hodgkin's disease in the BNLI: a 20-year experience. British National Lymphoma Investigation. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO*. 1991;2 Suppl 2:83-92.
26. Tucker MA, Coleman CN, Cox RS, Varghese A, Rosenberg S. ARisk of second cancers after treatment for Hodgkin's disease. *N Engl J Med*. 1988;318:76-81.
27. Larson RA, LeBeau MM, Vardiman JW, Rowley JD. Myeloid leukemia after hematotoxins. *Environ Health Perspect*. 1996;104 Suppl 6:1303-1307.
28. American Cancer Society. Cancer in Children. 01/18/2013. Available at: <http://www.cancer.org/cancer/cancerinchildren/detailedguide/cancer-in-children-types-of-childhood-cancers>.
29. National Research Council. Childhood Cancer Survivorship: Improving Care and Quality of Life. Washington, DC: The National Academies Press; 2003.